MESO
Mesoblast LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.79B
P/E Ratio
—
EPS
$-0.74
Beta
0.82
52W High
$21.50
52W Low
$9.75
50-Day MA
$16.08
200-Day MA
$15.92
Dividend Yield
—
Profit Margin
-144.30%
Forward P/E
454.55
PEG Ratio
0.00
About Mesoblast Ltd
Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia.
Fundamentals
| Revenue (TTM) | $65.38M |
| Gross Profit (TTM) | $-23.23M |
| EBITDA | $-64.34M |
| Operating Margin | -55.20% |
| Return on Equity | -18.20% |
| Return on Assets | -6.16% |
| Revenue/Share (TTM) | $0.51 |
| Book Value | $0.45 |
| Price-to-Book | 3.33 |
| Price-to-Sales (TTM) | 27.39 |
| EV/Revenue | 29.01 |
| EV/EBITDA | -6.55 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1527.00% |
| Shares Outstanding | $128.85M |
| Float | $839.93M |
| % Insiders | 5.07% |
| % Institutions | 3.49% |
Analyst Ratings
Consensus ($35.00 target)
2
Strong Buy1
BuyData last updated: 4/8/2026